COEPTIS THERAPEUTICS HOLDING (COEP)
US19207A1088 - Common Stock
Taking everything into account, COEP scores 1 out of 10 in our fundamental rating. COEP was compared to 565 industry peers in the Biotechnology industry. Both the profitability and financial health of COEP have multiple concerns. COEP has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year COEP has reported negative net income.
In the past year COEP has reported a negative cash flow from operations.
In the past 5 years COEP always reported negative net income.
In the past 5 years COEP always reported negative operating cash flow.
1.2 Ratios
COEP's Return On Assets of -260.16% is on the low side compared to the rest of the industry. COEP is outperformed by 93.06% of its industry peers.
COEP's Return On Equity of -486.74% is on the low side compared to the rest of the industry. COEP is outperformed by 80.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -260.16% | ||
| ROE | -486.74% | ||
| ROIC | N/A |
ROA(3y)-312.32%
ROA(5y)N/A
ROE(3y)-615.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
COEP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, COEP has more shares outstanding
COEP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, COEP has an improved debt to assets ratio.
2.2 Solvency
COEP has an Altman-Z score of -22.11. This is a bad value and indicates that COEP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -22.11, COEP is not doing good in the industry: 87.54% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.03 indicates that COEP is not too dependend on debt financing.
COEP has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: COEP outperforms 40.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -22.11 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.76 indicates that COEP should not have too much problems paying its short term obligations.
COEP has a worse Current ratio (1.76) than 79.00% of its industry peers.
COEP has a Quick Ratio of 1.76. This is a normal value and indicates that COEP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.76, COEP is doing worse than 77.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
COEP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.52%, which is quite impressive.
EPS 1Y (TTM)74.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 15.64% on average over the next years. This is quite good.
COEP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.70% yearly.
EPS Next Y69.41%
EPS Next 2Y34.16%
EPS Next 3Y21.64%
EPS Next 5Y15.64%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y19.7%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
COEP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year COEP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as COEP's earnings are expected to grow with 21.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.16%
EPS Next 3Y21.64%
5. Dividend
5.1 Amount
No dividends for COEP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COEPTIS THERAPEUTICS HOLDING
NASDAQ:COEP (12/27/2024, 8:12:17 PM)
After market: 0.1601 -0.02 (-12.13%)0.1822
-0.03 (-13.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.22%
Inst Owner Change2.5%
Ins Owners13.12%
Ins Owner Change0%
Market Cap7.49M
Analysts43.33
Price Target3.06 (1579.47%)
Short Float %0.87%
Short Ratio0.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1072.39%
Min EPS beat(2)-2154.9%
Max EPS beat(2)10.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.74 | ||
| P/tB | 1.74 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -260.16% | ||
| ROE | -486.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-312.32%
ROA(5y)N/A
ROE(3y)-615.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | -22.11 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.75%
EPS Next Y69.41%
EPS Next 2Y34.16%
EPS Next 3Y21.64%
EPS Next 5Y15.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y19.7%
EBIT growth 1Y64.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year132.72%
EBIT Next 3Y-3%
EBIT Next 5Y14.87%
FCF growth 1Y-86.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.79%
OCF growth 3YN/A
OCF growth 5YN/A